Literature DB >> 24666391

In vivo opioid receptor heteromerization: where do we stand?

D Massotte1.   

Abstract

UNLABELLED: Opioid receptors are highly homologous GPCRs that modulate brain function at all levels of neural integration, including autonomous, sensory, emotional and cognitive processing. Opioid receptors functionally interact in vivo, but the underlying mechanisms involving direct receptor-receptor interactions, affecting signalling pathways or engaging different neuronal circuits, remain unsolved. Heteromer formation through direct physical interaction between two opioid receptors or between an opioid receptor and a non-opioid one has been postulated and can be characterized by specific ligand binding, receptor signalling and trafficking properties. However, despite numerous studies in heterologous systems, evidence for physical proximity in vivo is only available for a limited number of opioid heteromers, and their physiopathological implication remains largely unknown mostly due to the lack of appropriate tools. Nonetheless, data collected so far using endogenous receptors point to a crucial role for opioid heteromers as a molecular entity that could underlie human pathologies such as alcoholism, acute or chronic pain as well as psychiatric disorders. Opioid heteromers therefore stand as new therapeutic targets for the drug discovery field. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  GPCRs; addiction; fluorescent knock-in mice; heteromer; mood disorders; nociception; opioid receptors

Mesh:

Substances:

Year:  2014        PMID: 24666391      PMCID: PMC4292957          DOI: 10.1111/bph.12702

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  132 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation.

Authors:  Kamran Salim; Tim Fenton; Jamil Bacha; Hector Urien-Rodriguez; Tim Bonnert; Heather A Skynner; Emma Watts; Julie Kerby; Anne Heald; Margaret Beer; George McAllister; Paul C Guest
Journal:  J Biol Chem       Date:  2002-02-19       Impact factor: 5.157

3.  Promiscuous coupling at receptor-Galpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another.

Authors:  Paola Molinari; Caterina Ambrosio; Daniela Riitano; Maria Sbraccia; Maria Cristina Grò; Tommaso Costa
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

4.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.

Authors:  Rashmi G Bhushan; Shiv K Sharma; Zhihua Xie; David J Daniels; Philip S Portoghese
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

Review 5.  Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling.

Authors:  Martin J Lohse; Susanne Nuber; Carsten Hoffmann
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

6.  Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

7.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

8.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

9.  ORL1 receptor-mediated internalization of N-type calcium channels.

Authors:  Christophe Altier; Houman Khosravani; Rhian M Evans; Shahid Hameed; Jean B Peloquin; Brian A Vartian; Lina Chen; Aaron M Beedle; Stephen S G Ferguson; Alexandre Mezghrani; Stefan J Dubel; Emmanuel Bourinet; John E McRory; Gerald W Zamponi
Journal:  Nat Neurosci       Date:  2005-11-27       Impact factor: 24.884

10.  In vivo delta opioid receptor internalization controls behavioral effects of agonists.

Authors:  Amynah A A Pradhan; Jérôme A J Becker; Grégory Scherrer; Petra Tryoen-Toth; Dominique Filliol; Audrey Matifas; Dominique Massotte; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

View more
  10 in total

1.  In vivo neuronal co-expression of mu and delta opioid receptors uncovers new therapeutic perspectives.

Authors:  Eric Erbs; Lauren Faget; Pierre Veinante; Brigitte L Kieffer; Dominique Massotte
Journal:  Receptors Clin Investig       Date:  2014-09

2.  Themed section.

Authors:  M J Christie; M Connor; J R Traynor
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

3.  Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.

Authors:  Kévin Carayon; Lionel Moulédous; Anne Combedazou; Serge Mazères; Evert Haanappel; Laurence Salomé; Catherine Mollereau
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

4.  A Model of Δ9-Tetrahydrocannabinol Self-administration and Reinstatement That Alters Synaptic Plasticity in Nucleus Accumbens.

Authors:  Sade Spencer; Daniela Neuhofer; Vivian C Chioma; Constanza Garcia-Keller; Danielle J Schwartz; Nicholas Allen; Michael D Scofield; Tara Ortiz-Ithier; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2018-05-03       Impact factor: 13.382

Review 5.  Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.

Authors:  Katia Befort
Journal:  Front Pharmacol       Date:  2015-02-05       Impact factor: 5.810

Review 6.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

Review 7.  Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity.

Authors:  Georgina L Thompson; Meritxell Canals; Daniel P Poole
Journal:  Front Pharmacol       Date:  2014-11-28       Impact factor: 5.810

8.  In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice.

Authors:  Roberta Lattanzi; Silvia Rief; Helmut Schmidhammer; Lucia Negri; Mariana Spetea
Journal:  Front Pharmacol       Date:  2018-08-31       Impact factor: 5.810

9.  CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid Receptors.

Authors:  Laurie-Anne Roeckel; Dominique Massotte; Mary C Olmstead; Katia Befort
Journal:  Front Psychiatry       Date:  2018-11-27       Impact factor: 4.157

10.  Selective and Wash-Resistant Fluorescent Dihydrocodeinone Derivatives Allow Single-Molecule Imaging of μ-Opioid Receptor Dimerization.

Authors:  Christian Gentzsch; Kerstin Seier; Antonios Drakopoulos; Marie-Lise Jobin; Yann Lanoiselée; Zsombor Koszegi; Damien Maurel; Rémy Sounier; Harald Hübner; Peter Gmeiner; Sébastien Granier; Davide Calebiro; Michael Decker
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-07       Impact factor: 16.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.